Endocrine disrupting compounds and prostate cancer.

J K Hess-Wilson, K E Knudsen

Journal: Cancer letters 2006;241(1):1-12

PMID: 16298040

Abstract

Prostate cancer is a major health concern and is treated based on its hormone dependence. Agents that alter hormone action can have substantial biological effects on prostate cancer development and progression. As such, there is significant interest in uncovering the potential effects of endocrine disrupting compound (EDC) exposure on prostate cancer. The present review is focused on agents that alter hormone action in the prostate and how they may impact cancer growth or treatment.

Address: Department of Cell Biology, University of Cincinnati College of Medicine, P.O. Box 670521, 3125 Eden Ave., Cincinnati, OH 45267-0521, USA.

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.